Frontage ran a Phase I Study of OMN54 (Aneustat™) in patients with advanced malignancies.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
This webinar discusses smart processes to include in your Phase 1 clinical development program to save time and cost yet add value to your clinical asset. Cut time, not corners.
In this webinar, we discuss the strategies to overcome challenges during formulation development, various technologies available for formulation development, and Frontage CMC's unique capabilities.
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.